YOLFTbeta
Pharming Group N.V.

Pharming Group N.V.

0QCO · LSE

1.14EUR-0.02 (-1.30%)

Price History

Full chart

Market Stats

Previous Close1.15
Open1.15
Day Range1.14 – 1.19
52-Week Range0.8339 – 1.83
Volume3.00K
Market Cap501.40M
P/E (TTM)0.54
Forward P/E0.00
EPS0.015
Dividend Yield0.00%
Beta0.07
50-Day Avg1.10
200-Day Avg1.12

About

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K" inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Company Details

  • CEOMr. Kenneth Lynard EMBA, M.Sc.
  • Employees407
  • HeadquartersDarwinweg 24, Leiden, Netherlands, 2333 CR, UK
  • Websitehttps://www.pharming.com

Leadership

  • Mr. Kenneth Lynard EMBA, M.Sc.Chief Financial Officer · b. 1968
  • Ms. Mireille Sanders M.Sc.Chief Operations Officer · b. 1968
  • Mr. Michael K. LevitanVP of Investor Relations & Corporate Communications
  • Mr. Ruud Van Outersterp L.L.M.Chief Legal & Compliance Officer and Company Secretary · b. 1964
  • Ms. Ines Bernal B.A.Chief People Officer
  • Dr. Anurag Relan M.D., MPHChief Medical Officer · b. 1972
  • Dr. Alexander Breidenbach M.B.A., Ph.D.Chief Business Officer · b. 1963
  • Ms. Leverne Marsh BPHARMChief Commercial Officer
  • Dr. Magnus HanssonMedical Director · b. 1976
  • Dr. Bruno M. L. GiannettiConsultant · b. 1952

Financials

Income Statement

Currency: EUR2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-31
Total Revenue15.87M89.62M135.13M169.02M185.69M--
Growth (%)-+464.61%+50.78%+25.08%+9.86%--
Cost of Revenue4.68M12.45M22.18M21.36M20.60M--
Gross Profit11.19M77.17M112.95M147.67M165.09M--
Gross Margin70.50%86.11%83.59%87.37%88.91%--
Operating Expense22.73M55.26M74.96M86.76M98.35M--
Operating Income-11.54M21.91M37.99M60.91M66.74M--
Operating Margin-72.70%24.45%28.12%36.03%35.94%--
Net Income-17.54M-76.25M24.99M36.20M33.03M--
Net Income Margin-110.48%-85.08%18.50%21.41%17.79%--
Interest Expense000000-
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%--

Balance Sheet

Currency: EUR2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-31
Total Assets126.78M166.19M214.48M228.21M340.76M--
Total Liabilities99.32M150.08M152.73M123.53M191.38M--
Total Equity27.47M16.11M61.75M104.68M149.38M--
Cash31.89M58.66M80.31M66.30M167.07M--
Total Debt40.99M59.55M37.43M4.36M128.63M--

Cash Flow

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Operating Cash Flow-10.00M38.21M40.38M66.50M83.63M37.84M22.90M--
Investing Cash Flow-57.47M-6.04M-3.77M-25.22M-15.63M-21.30M5.32M--
Financing Cash Flow67.33M-3.25M-17.96M-56.65M60.69M-27.95M-4.98M--
Capital Expenditure1.19M3.25M2.50M22.71M4.66M10.74M1.38M00

Earnings

Report DateSep 30, 2008Dec 31, 2008Mar 31, 2009Jun 30, 2009Sep 30, 2009Dec 31, 2009Mar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Mar 14, 2024May 8, 2024Aug 1, 2024Oct 24, 2024Mar 12, 2025May 6, 2025Jul 31, 2025Nov 6, 2025Mar 12, 2026May 7, 2026Jul 30, 2026Nov 5, 2026
EPS Estimate---------------------------------------------------------------------0.01--0.01
EPS Actual-0.79-0.39-0.62-0.89-0.70-0.60-0.49-1.14-0.19-0.40-0.08-0.10-0.12-0.08-0.12-0.17-0.120.00-0.05-0.01-0.02-0.01-0.04-0.010.000.03-0.00-0.01-0.01-0.01-0.01-0.01-0.01-0.02-0.01-0.05-0.01-0.070.010.010.010.020.010.010.020.020.010.010.010.010.010.01-0.000.000.000.020.01-0.02-0.020.000.00-0.00-0.02-0.00-0.000.01-0.020.010.010.01-0.010.00-
Surprise----------------------------------------------------------------------40.00%---
Timing-------------------------------------------------------------Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-market

Key Statistics & Ratios

Market Cap501.40M
Enterprise Value582.96M
Trailing P/E0.54
Forward P/E0.00
Price / Sales1.33
Price / Book0.00
EPS0.015
Book Value0.3369
Revenue (TTM)366.48M
Gross Profit (TTM)317.08M
EBITDA32.88M
Profit Margin2.54%
Operating Margin1.46%
Return on Equity3.65%
Return on Assets3.47%
Shares Outstanding638.56M
Shares Float696.57M
Beta0.07
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Nov 23, 2016805:799
  • Mar 5, 20131:10